Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sandoz Group AG's revenue for the
six
months ended in Jun. 2026 was €5,021 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was €10,052 Mil.
Sandoz Group AG's Revenue per Share for the
six
months ended in Jun. 2026 was €11.45.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was €22.95.
During the past 12 months, the average Revenue per Share Growth Rate of Sandoz Group AG was 2.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 0.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 4 years, Sandoz Group AG's highest 3-Year average Revenue per Share Growth Rate was 0.40% per year. The lowest was 0.40% per year. And the median was 0.40% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Sandoz Group AG Revenue Related Terms
Sandoz Group AG Revenue Historical Data
* Premium members only.
The historical data trend for Sandoz Group AG's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sandoz Group AG Revenue vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's Revenue distribution charts can be found below:
* The bar in red indicates where Sandoz Group AG's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was €10,052 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sandoz Group AG (FRA:D8Y) has a Revenue of €10,052 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Sandoz Group AG and its competitors.
Is Sandoz Group AG's Revenue too high?
Sandoz Group AG's current Revenue is €10,052 Mil. Overall, Sandoz Group AG has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sandoz Group AG's Revenue compare to ZTS and UTHR?
Sandoz Group AG's Revenue of €10,052 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Sandoz Group AG and its competitors. Sandoz Group AG's current Revenue is €10,052 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sandoz Group AG stock overvalued right now?
Based on GuruFocus' analysis, Sandoz Group AG (FRA:D8Y) is currently considered Significantly Overvalued. The stock's GF Value™ is €51.13, compared to a current price of €76.96 — trading 50.5% above its estimated fair value. The current Revenue is €10,052 Mil. Sandoz Group AG's overall GF Score™ is 27/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Sandoz Group AG (FRA:D8Y), the current Revenue is €10,052 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sandoz Group AG (FRA:D8Y) Overvalued in 2026?
Based on GuruFocus' analysis, Sandoz Group AG stock appears to be overvalued.
The current stock price of €76.96 is trading 50.5% above its estimated GF Value™ of €51.13.
GuruFocus considers Sandoz Group AG to be Significantly Overvalued.
Key valuation signals for FRA:D8Y:
Revenue: €10,052 Mil
GF Value™: €51.13 vs. price of €76.96 (50.5% above fair value)
No single metric tells the full story. See the FRA:D8Y stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $11 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It has over 10 launched biosimilars in a number of markets and over 20 assets in its pipeline.
27GF Score
Get the complete analysis for FRA:D8Y
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:D8Y has been successfully added to your 
